Do we have enough evidence for recommending therapeutic plasma exchange for patients with natalizumab ‐associated progressive multifocal leukoencephalopathy?
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 15, 2018 Category: Hematology Source Type: research
---
Journal of Clinical Apheresis, Ahead of Print. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 15, 2018 Category: Hematology Source Type: research
Do we have enough evidence for recommending therapeutic apheresis for natalizumab ‐related progressive multifocal leukoencephalopathy patients? Comment on “Guidelines on the use of therapeutic apheresis in clinical practice‐evidence‐based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.”
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 12, 2018 Category: Hematology Source Type: research
---
Journal of Clinical Apheresis, Ahead of Print. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 12, 2018 Category: Hematology Source Type: research
Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 10, 2018 Category: Hematology Source Type: research
---
Journal of Clinical Apheresis, Ahead of Print. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 10, 2018 Category: Hematology Source Type: research
Therapeutic plasma exchange: Experience in a third level hospital, 2013 –2016, Lima (Peru)
This study reports a low rate of complications, suggesting that TPE is safe. There is a need to create a multicenter Peruvian apheresis registry to assess the benefits and risks of TPE in Peru. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 1, 2018 Category: Hematology Authors: Luis Palma ‐Garcia, Victor Velásquez‐Rimachi, Armando Pezo‐Pezo, Joseph Roig, Julio Perez‐Villegas Tags: RESEARCH ARTICLE Source Type: research
Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study
ConclusionsTPE is an important therapeutic modality in cardiac transplant patients. Prospective studies are needed to better define TPE's different roles in this patient population. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 1, 2018 Category: Hematology Authors: Oluwatoyosi A. Onwuemene, Steven C. Grambow, Chetan B. Patel, Robert J. Mentz, Carmelo A. Milano, Joseph G. Rogers, Ara D. Metjian, Gowthami M. Arepally, Thomas L. Ortel Tags: RESEARCH ARTICLE Source Type: research
The use of cytapheresis in the treatment of infectious diseases
Cytapheresis (removal of cellular blood components) has been employed for treatment of infectious diseases since the 1960s. Techniques have included thrombocytapheresis (buffy coat apheresis) for loiasis, erythrocytapheresis for malaria and babesiosis, and leukocytapheresis for pertussis‐associated lymphocytosis. Published data on these applications is largely limited to case level data and small observational studies; as such, recommendations for or against the use of cytapheresis in the treatment of infections have been extrapolated from these limited (and at times flawed) data sets. Consequently, utilization of cytaph...
Source: Journal of Clinical Apheresis - February 1, 2018 Category: Hematology Authors: Andrew P. Norgan, Justin E. Juskewitch, Bobbi S. Pritt, Jeffrey L. Winters Tags: CONCISE REVIEWS Source Type: research
Comparison of the CMNC and MNC apheresis protocol for the collection of T ‐cells showed comparable outcome: An observational study in a single centre
ConclusionThe CMNC and MNC protocols are reliable, efficient and comparable in performance parameters and cell composition of final product, respectively. One advantages of the CMNC protocol is the potential ability to tailor the cell composition of the final product accordingly to demands from cell processing laboratories. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 1, 2018 Category: Hematology Authors: Daniel Putensen, Richard Smith, Linda Pilcher, George Trandafir Tags: RESEARCH ARTICLE Source Type: research
Do we have enough evidence for recommending therapeutic plasma exchange for patients with natalizumab ‐associated progressive multifocal leukoencephalopathy?
(Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 1, 2018 Category: Hematology Authors: Huy P. Pham, Dheeraj Raju, Joseph Schwartz Tags: LETTER TO THE EDITOR Source Type: research
Do we have enough evidence for recommending therapeutic apheresis for natalizumab ‐related progressive multifocal leukoencephalopathy patients? Comment on “Guidelines on the use of therapeutic apheresis in clinical practice‐evidence‐based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.”
(Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - February 1, 2018 Category: Hematology Authors: Doriana Landi, Diego Centonze, Girolama Alessandra Marfia, Ruggero Capra, Cristina Scarpazza Tags: LETTER TO THE EDITOR Source Type: research
Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy
This report describes a patient with light chain myeloma and acute renal injury. Serum kappa free light chain (FLC) was extremely elevated, >33,000 mg/dL. Treatment with therapeutic plasma exchange (TPE) started day 2 for biopsy‐confirmed cast nephropathy. Bortezomib‐containing chemotherapy was initiated on day 5, and hemodialysis for tumor lysis syndrome on day 7. TPE alone decreased kappa FLC >70% by day 5, indicating direct FLC removal was successful in this patient. A total of 25 TPE procedures were performed in a 31‐day hospitalization. Hemodialysis was discontinued after 3 months, and the patient's renal ...
Source: Journal of Clinical Apheresis - February 1, 2018 Category: Hematology Authors: Christine L. H. Snozek, Theresa N. Kinard, Jill Adamski Tags: CASE REPORT Source Type: research
Thrombotic microangiopathy in the setting of human immunodeficiency virus infection: High incidence of severe thrombocytopenia
ConclusionsThe incidence described herein of HIV infection among TMA patients is the highest reported outside of South Africa. More severe thrombocytopenia in HIV‐positive patients may reflect TMA in the setting of preexisting HIV‐associated thrombocytopenia. HIV should be considered in patients with TMA, and TMA should be considered in HIV‐positive patients with severe thrombocytopenia. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - January 27, 2018 Category: Hematology Authors: Najeebah A. Bade, Victoria S. Giffi, Maria R. Baer, Ann B. Zimrin, Jennie Y. Law Tags: RESEARCH ARTICLE Source Type: research
Thrombotic microangiopathy in the setting of human immunodeficiency virus infection: High incidence of severe thrombocytopenia
Journal of Clinical Apheresis, EarlyView. (Source: Journal of Clinical Apheresis)
Source: Journal of Clinical Apheresis - January 26, 2018 Category: Hematology Source Type: research
